915 / 1851
Conclusions – PCNSL
MTX + Rituximab containing regimen
is significantly more active and effective than the other
combinations leading to high rates of CR (
≃
50%) and ORR (85-90%), and should be considered the
new standard induction for PCNSL
A Consolidative therapy is strongly recommended
after induction chemotherapy for PCNSL
WBRT and ASCT are both active and effective
, as consolidation therapies after high-dose-
methotrexate-based chemoimmunotherapy with a 95% CR rate, and 75-80% progression-free
survivors at 2 years
The best consolidative approach
should be selected “case by case” and tailored to the patients
within a multidisciplinary tumor board, taking into account the toxicity profile of each strategy.